FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Venlo, the Netherlands, Sept. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced an important milestone with the launch of 100 new assays for its digital ...

Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

VENLO, the Netherlands, April 29, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced ...

Qiagen N.V. (QGEN) announced that its SARS-CoV-2 polymerase chain reaction (PCR) tests remain accurate and effective against the new variant Omnicron. The Omnicron variant, which has emerged from ...

IP portfolio now includes high-resolution melting-curve analysis applications for research and diagnostic development. Qiagen acquired licenses from Roche and Idaho Technology related to the use of ...

Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy ...

QIAGEN N.V. QGEN recently announced the expansion of its digital PCR (dPCR) offering for the biopharma sector's cell and gene therapy development in partnership with Niba Labs. The recent development ...